After Being up 1,035%, Raising $11 Million, Upgrading to NASDAQ, and Retreating 87% From its High, we Resume Coverage.
Tale of the Tape.
This is just a heads up, we are resuming coverage – with more to come later including the upcoming official launch of SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses. The product works, there are plenty of real-testimonials of their website. We hate the saying, but this really is a ‘game-changer’ for the treatment of pets and horses.
- July 24th, 2019: Biotech Stock Review Adding PetVivo (PETV) $0.23 to the Watch List.
- December 18th, 2020: And Slowly But Surely..We Have Another 10-Bagger. PetVivo (PETV).
- June 10th, 2021: Discontinuing Coverage of PetVivo (PETV), a Gain of 1,035%.
- August 23rd, 2021: Resuming Coverage on PetVivo (PETV) $2.75.
Website: PetVivo Holdings.
Down 87% from it’s high of $17 in December of 2020, it’s always difficult to pick an absolute bottom – but we’ll venture to guess we are close. We predict a very bright future and a year ahead, packed with news.
The most important thing in our opinion, is they now have the funding ($11 million raised) to market their wonder treatment.
The market cap is still to tiny for institutions, so this is ‘all ours’ for the time being. Good luck and good hunting.
PS: There are an estimated 14 million dogs and one million horses suffering from “wear and tear” arthritis affecting the hips and knees. The treatment is $500 to $700 – you do the math!
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product Kush, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.
Forward Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
John Lai, CEO
PetVivo Holdings, Inc.